Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 21:00:02 13/09/2024 BST 5-day change 1st Jan Change
165.52 USD +0.53% Intraday chart for Johnson & Johnson +0.69% +5.60%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HSBC Raises Price Target on Johnson & Johnson to $180 From $174 MT
Johnson & Johnson Unit Submits Marketing Application in Europe for Nipocalimab to Treat Generalized Myasthenia Gravis MT
J&J Unit Seeks EU Approval for Chronic Neuromuscular Disease Drug MT
ECB to cut rates without lowering its guard Our Logo
Johnson & Johnson Secures FDA Approval for Tremfya as Ulcerative Colitis Treatment MT
J&J: FDA approves Tremfya for ulcerative colitis CF
J&J CFO Sees Value in Tech Partnerships MT
How J&J's CFO Keeps His Footing on the 'Patent Cliff' MT
J&J: positive trial for dexamethasone CF
The mood is getting heavier, but Taylor Swift is keeping watch Our Logo
Johnson & Johnson Phase 2 Trial of Potential Lung Cancer Treatment Meets Primary Endpoint MT
Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes CI
J&J: positive study in lung cancer CF
Johnson & Johnson's Lung Cancer Therapy Shows Improved Long-Term Survival in Phase 3 Study MT
Johnson & Johnson's Lung Cancer Therapy Shows Improved Long-Term Survival in Phase 3 Study MT
Veeva Systems: leader in cloud solutions for the life sciences industry Our Logo
Transcript : Johnson & Johnson Presents at Wells Fargo 2024 Healthcare Conference, Sep-05-2024 11:00 AM
Such a long wait Our Logo
Johnson & Johnson Gets Plaintiff Lawyer's Support on Upsized Talc Settlement Plan MT
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Retreat Wednesday Afternoon MT
Sector Update: Health Care MT
Top Midday Stories: Nvidia Gets DOJ Subpoena as Antitrust Probe Intensifies; Nippon Steel Deal Failure Puts Thousands of US Jobs at Risk, US Steel Says MT
Johnson & Johnson Ordered to Pay Over $1 Billion in Surgical Robot Acquisition Case MT
Johnson & Johnson Ordered to Pay Over $1 Billion in Surgical Robots Acquisition Case MT
Chart Johnson & Johnson
More charts
Logo Johnson & Johnson
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Employees
131,900
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
165.52USD
Average target price
171.32USD
Spread / Average Target
+3.51%
Consensus
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. News Johnson & Johnson
  5. Sector Update: Health Care Stocks Higher Wednesday Afternoon
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW